Login to Your Account

Eye Kidney Not: Lux Phase III Fizzles, Isotechnika to Refocus

By Randy Osborne
Staff Writer

Friday, December 28, 2012
Now that licensing partner Lux Biosciences Inc. has lifted the lid on short-of-the-mark Phase III results from another try with voclosporin for uveitis, Isotechnika Pharma Inc. is turning its attention fully to nephrology – especially kidney transplants, the indication for which the calcineurin inhibitor originally was designed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription